| Yang, Jun Ying |
| Completed | 3 | 295 | Europe, US, RoW | Telmisartan 10 mg/amlodipine 1.25 mg/indapamide 0.625 mg, Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, Placebo | George Medicines PTY Limited | Hypertension | 09/23 | 10/23 | | |
GMRx2_ACT, NCT04518293: Efficacy and Safety of GMRx2 Compared to Dual Combinations for the Treatment of Hypertension |
|
|
| Completed | 3 | 1385 | Europe, US, RoW | Telmisartan 20 mg/amlodipine 2.5 mg/indapamide 1.25 mg, telmisartan 40 mg/amlodipine 5 mg/indapamide 2.5 mg, Telmisartan 20 mg/amlodipine 2.5 mg ., telmisartan 40 mg/amlodipine 5 mg, Telmisartan 20 mg/indapamide 1.25 mg, telmisartan 40 mg/indapamide 2.5 mg, Amlodipine 2.5 mg/indapamide 1.25 mg, amlodipine 5 mg/indapamide 2.5 mg | George Medicines PTY Limited | Hypertension | 08/23 | 09/23 | | |
NCT06198764: A Clinical Trial for the Treatment of Carbapenem Resistant Gram-negative Bacterial Infection With Colistimethate Sodium for Injection |
|
|
| Recruiting | 3 | 80 | RoW | Colistimethate sodium for injection, Meropenem for Injection, Coly Mycin M Injectable Product | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Mental Health Issue | 03/26 | 03/26 | | |
NCT04409080 / 2020-002031-29: REGN7257 in Adult Patients With Severe Aplastic Anemia That Is Refractory to or Relapsed on Immunosuppressive Therapy |
|
|
| Suspended | 1/2 | 33 | Europe, US, RoW | REGN7257 | Regeneron Pharmaceuticals, Regeneron Pharmaceuticals, Inc | Severe Aplastic Anemia (SAA) | 01/26 | 07/26 | | |
| Recruiting | 1 | 96 | RoW | BL-B01D1 | Sichuan Baili Pharmaceutical Co., Ltd., SystImmune Inc. | Locally Advanced or Metastatic Solid Tumor | 06/25 | 12/25 | | |
TRIPHY, NCT06480890: Real-World Effectiveness of a Triple Combination BDP/FF/GB in a Single Pressurised Metered Dose Inhaler in COPD Patients |
|
|
| Recruiting | N/A | 359 | RoW | | Chiesi Farmaceutici S.p.A. | Chronic Obstructive Pulmonary Disease | 10/25 | 10/25 | | |
